Risdiplam Under FDA Review & How the Lack of SMA Protein May Also Directly Contribute to SMA - a podcast by SMA News Today

Anticipation is growing as Roche/Genentech's treatment risdiplam, the first oral medication to treat SMA, is under FDA review.

SMA News Today’s multimedia associate, Price Wooldridge, discusses how the lack of SMA protein may also directly contribute to SMA.
Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

Further episodes of SMA News & Perspectives

Further podcasts by SMA News Today

Website of SMA News Today